NCT Neuro Master Match (N2M2) trial

The German National Center for Tumor Diseases (NCT) has developed a noncomparative screening trial called Neuro Master Match (N2M2) for first-line unmethylated glioblastoma classification.

The NCT Neuro Master Match (N2M2) trial is an open-label, multicenterphase 1/IIa umbrella trial for patients with newly diagnosed Glioblastoma IDH wildtype without MGMT promoter hypermethylation to show safety, feasibility, and preliminary efficacy of treatment with targeted compounds in addition to standard radiotherapy based on molecular characterization. N2M2 is formally divided into a Discovery and a Treatment part. Discovery includes broad molecular neuropathological diagnostics to detect predefined biomarkers for targeted treatments. Molecular diagnostics and bioinformatics are performed within 4 weeks, allowing a timely initiation of postoperative treatment. Stratification for Treatment takes place in 5 subtrials, including alectinibidasanutlinpalbociclibvismodegib, and temsirolimus as targeted therapies, according to the best matching molecular alteration. Patients without matching alterations are randomized between subtrials without strong biomarkers using atezolizumab and asinercept(APG101) and the standard of care, TMZ. For the phase I parts, a Bayesian criterion is used for continuous monitoring of toxicity. In the phase 2trials, progression-free survival at 6 months is used as endpoint for efficacy.

Molecular diagnostics and bioinformatic evaluation are performed within 4 weeks, allowing a timely initiation of postoperative treatment. Stratification for Treatment takes place in 5 subtrials, including alectinib, idasanutlin, palbociclib, vismodegib, and temsirolimus as targeted therapies, according to the best matching molecular alteration. Patients without matching alterations are randomized between subtrials without strong biomarkers using atezolizumab and asinercept (APG101) and the standard of care, TMZ. For the phase I parts, a Bayesian criterion is used for continuous monitoring of toxicity. In the phase II trials, progression-free survival at 6 months is used as endpoint for efficacy.

Molecularly informed trials may provide the basis for the development of predictive biomarkers and help to understand and select patient subgroups who will benefit 1).


The N2M2 study represents a significant advance in study design for evaluation of drugs in the early phase II space for newly diagnosed GBM. It will be of great interest to the field to see how this design plays out in “real life,” and whether any of the substudies show evidence of efficacy in their target populations. Furthermore, the practical experience of using extensive multiplatform biomarker data in a large, prospective platform study will aid other platform efforts in the field, including adaptive studies such as INSIGhT 2) 3) and GBM AGILE, 4) which target the later phase II and phase III areas of drug evaluation for both newly diagnosed and recurrent GBM 5).

References

1)

Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahm F, Platten M. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro Oncol. 2019 Jan 1;21(1):95-105. doi: 10.1093/neuonc/noy161. PubMed PMID: 30277538.
2)

Tanguturi SK, Trippa L, Ramkissoon SH, et al. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017;19(7):908–917.
3)

Colman H. Toward more informative biomarker-based clinical trials in glioblastoma. Neuro Oncol. 2017;19(7):880–881
4)

Alexander BM, Ba S, Berger MS, et al; GBM AGILE Network. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin Cancer Res. 2018;24(4):737–743.
5)

Colman H. A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma. Neuro Oncol. 2019 Jan 1;21(1):6-7. doi: 10.1093/neuonc/noy190. PubMed PMID: 30590837.

Eso Masterclass In Neuro-Oncology: Multidisciplinary Management Of Adult Brain Tumour

September 20 — September 22

Milan, Italy

Programme

The European School of Oncology was founded by Umberto Veronesi and Laudomia Del Drago in 1982, with the aim of contributing to the reduction of deaths from cancer due to late diagnosis and/or inadequate treatment. By improving the skills of all health professionals dealing with cancer patients, ESO helps shorten the time needed to transfer knowledge from research centres to daily practice, combining advanced technology with humanism in care.

ESO’s mission is reflected in its motto “Learning to Care”, which emphasises the importance of the learning process, and the goal of caring for the patient in a holistic sense, in contrast to focusing purely on treating the disease.

Due to its financial independence, ESO has the rare privilege of being able to set its own priorities. It therefore pays particular attention to developing the transfer of knowledge in areas that are least supported by industry, such as surgery and in rare pathologies (including childhood tumours), and in countries and regions with limited economic resources.

Fluorescence-Guided Neurosurgery: Neuro-oncology and Cerebrovascular Applications

The definitive textbook on state-of-the-art fluorescence-guided neurosurgery

Advances in fluorescence-guided surgery (FGS) have resulted in a paradigm shift in neurosurgical approaches to neuro-oncological and cerebrovascular pathologies. Edited by two of the foremost authorities on the topic, Fluorescence-Guided Neurosurgery: Neuro-oncology and Cerebrovascular Applications encompasses the depth and breadth of this groundbreaking, still nascent technology. The book reflects significant contributions made by world renowned neurosurgeons Constantinos Hadjipanayis, Walter Stummer, and esteemed contributors on the growing uses of 5-aminolevulinic acid (5-ALA) and other FGS agents.

The European Medicine Agency approved 5-ALA in 2007, heralding the birth of FGS globally. In 2017, the U.S. Food and Drug Administration approved 5-ALA (Gleolan) as an imaging agent to facilitate realtime detection and visualization of malignant tissue during glioma surgery. In the two decades since Dr. Stummer’s initial description of 5-ALA FGS in a human patient, major strides have been made in its practical applications, leading to improved resection outcomes. As FGS is increasingly incorporated into neurosurgical practice, it holds promise for future innovations. Generously-illustrated and enhanced with online videos, this textbook is the definitive resource on the subject.

Key Features

  • The improved efficacy of 5-ALA for resecting high- and low-grade gliomas, recurrences, meningiomas, brain metastases, spinal cord tumors, pediatric brain tumors, and other adult tumors
  • The future of fluorescence, including potentially powerful new fluorophores molecularly targeted specifically to tumors
  • The use of the fluorescent agent indocyanine green (ICG) for brain tumors, cerebral aneurysms, AVMs, and cerebral vascularization
  • Special topics such as fluorescein, illuminating tumor paint, confocal microscopy, Raman spectroscopy, and integrating FGS with intraoperative imaging and brain mapping

This single accessible reference presents the current state-of-the-art on this emerging, exciting surgical technology. As such, it is a must-have for neurosurgical residents, fellows, and practicing neurosurgeons.

 

 

Manual of Neuro-Surgery

Manual of Neuro-Surgery


Manual of Neuro-Surgery (Classic Reprint) Hardcover – April 21, 2018 by United States Surgeon General (Author)
Excerpt from Manual of Neuro-Surgery
ADD TO SHOPPING CART
Spine and Spinal Cord, by Dr. Charles H. Frazier; and from the technic of the suboccipital operation in Tumors of the Nervus Acusticus, by Dr. Harvey Cushing. Free use has been made of Diagnosis of Nervous Diseases, by Purves Stewart; of Tinel’s monograph on Nerve Wounds and of the Proceedings of the Royal Society of Medicine, 1915 – 16, Volume X, part 3. Valuable illustrations have been reproduced from Diseases of the Eye, by de Schweinitz.
Forgotten Books publishes hundreds of thousands of rare and classic books. Find more at www.forgottenbooks.com
This book is a reproduction of an important historical work. Forgotten Books uses state-of-the-art technology to digitally reconstruct the work, preserving the original format whilst repairing imperfections present in the aged copy. In rare cases, an imperfection in the original, such as a blemish or missing page, may be replicated in our edition. We do, however, repair the vast majority of imperfections successfully; any imperfections that remain are intentionally left to preserve the state of such historical works.

4º Beca Gebro Pharma SENEC – Grupo de Trabajo Neuro-Oncología

Se convoca para el año 2018 la 4º Beca Gebro Pharma SENEC – Grupo de Trabajo Neuro-Oncología.

Plazo límite: 28 de febrero de 2018
Los interesados deberán rellenar la solicitud adjunta y remitirla al Dr. José Hinojosa,   secretaria@senec.es

INSIGHTEC’S EXABLATE NEURO NAMED BEST MEDICAL TECHNOLOGY AT ESTEEMED PRIX GALIEN AWARDS 2017

INSIGHTEC, the leader in MR-guided Focused Ultrasound (MRgFUS), has been awarded Best Medical Technology for Exablate Neuro by The Galien Foundation.  Exablate Neuro is an innovative medical technology that uses focused ultrasound coupled with MR imaging (MRgFUS), to precisely target and treat areas deep within the brain through an intact skull.
The prestigious Prix Galien awards recognize excellence in scientific innovations that improve the state of human health. The Best Medical Technology award confirms INSIGHTEC’s vision of transformative healthcare and the company’s determination to improve the daily lives of patients living with essential tremor.
“It’s a great honor to receive this award, which recognizes our dedication to researching and developing a non-invasive medical treatment,” said INSIGHTEC’s CEO and Chairman of the Board, Maurice R. Ferré MD. “Our pursuit of innovation is not only driven by our founder Kobi Vortman, but also by the leading neurosurgery centers which have adopted the Exablate Neuro around the world. This is an exciting time for INSIGHTEC and spurs on our commitment to supporting healthcare professionals, deliver treatments which truly improve the lives of people worldwide.”
Having accepted the award at The American Museum of Natural History in New York City, INSIGHTEC’s Vice President of Marketing, Xen Mendelsohn Aderka added “To be seen as an innovator whilst in the presence of so many renowned figures in the pharmaceutical, biomedical and medical technology industry, is a great accolade. We thank the judges for acknowledging the hard work and dedication of our team.”
The U.S. Food and Drug Administration (FDA) approved Exablate Neuro in July 2016 for the non-invasive treatment of patients with essential tremor who had not responded to medication. Essential tremor is the most common movement disorder, affecting more than 5 million people in the United States, and millions more worldwide. Hand tremor is the most common symptom and for these patients, performing everyday tasks can seem nearly impossible and greatly impacts on their quality of life.

Actualización y Evidencias en Neuro-Oncología: Avances, Tecnología e Innovación en el Tratamiento Quirúrgico de los Tumores del SNC

Actualización y Evidencias en Neuro-Oncología: Avances, Tecnología e Innovación en el Tratamiento Quirúrgico de los Tumores del SNC

Para residentes a celebrar los días 24, 25 y 26 de Septiembre 2017 en el Hotel Spa Porta Maris de Alicante
Más información

Book: Neuro Spinal Surgery Operative Techniques: Micro Lumbar Discectomy: The Gold Standard

Neuro Spinal Surgery Operative Techniques: Micro Lumbar Discectomy: The Gold Standard
By Jkbc Parthiban

Neuro Spinal Surgery Operative Techniques: Micro Lumbar Discectomy: The Gold Standard
List Price: $114.00
ADD TO SHOPPING CART
Neuro Spinal Surgery Operative Techniques – Anterior Cervical Discectomy and Fusion is the latest book in the Neuro Spinal Surgery Operative Techniques series. This book covers Anterior Cervical Discectomy and Fusion (ACDF) in eight concise chapters. This surgical procedure involves decompressing the spinal cord and nerve roots in the neck. The first chapter covers the basic anatomy and approaches to ACDF, with illustrated guidance on microdiscectomy and bone grafting. Further chapters cover decompression of the nerve root and cord, interbody grafting technique, corpectomy and fusion, with the most current information on each procedure. The important technique of sinking’ the graft in the disc space to prevent graft migration is covered in detail. The final chapter provides information on instruments used in ACDF procedures. Neuro Spinal Surgery Operative Techniques – Anterior Cervical Discectomy and Fusion is enhanced by nearly 200 full colour images, making this an ideal quick reference guide for spine surgeons. Key Points Latest in Neuro Spinal Surgery Operative Techniques series Other topics in the series include Lateral Mass Fixation in Sub-axial Cervical Spine, and Cervical Laminoplasty 197 full colour images and illustrations


Product Details

  • Published on: 2017-08-01
  • Original language: English
  • Dimensions: 9.50″ h x .0″ w x 6.20″ l, 2.20 pounds
  • Binding: Paperback
  • 182 pages

Editorial Reviews

About the Author
JKBC Parthiban MCh (Neurosurgery) FNS Senior Consultant (Neurosurgery and Spine Neurosurgery), Kovai Medical Centre and Hospital, Coimbatore, Tamil Nadu, India

4th Pediatric Neuro-Oncology Basic and Translational Research Conference

4th Pediatric Neuro-Oncology Basic and Translational Research Conference

June 15 — June 16

New York, NY, USA
Hosted by the Society for Neuro-Oncology, taking place at the Wyndham New Yorker Hotel in New York, New York.
Website: http://www.soc-neuro-onc.org/pediatric-neurooncology-research-conference/
WhatsApp WhatsApp us
%d bloggers like this: